Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples